Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 868 participants.

Also called NCT03061214

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 868 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03061214
Other papers using this trial's data
  • Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial Diabetes, obesity & metabolism, 2021-02 DOI, PubMed 33074557, PMC7839591 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Brazil, China, Hong Kong SAR China, South Africa, South Korea, Taiwan, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03061214. Randomized; double masking; primary purpose treatment. Start 2017-08-28 (actual); primary completion 2019-03-14 (actual). Results posted on 2020-04-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
Acronym
SUSTAIN
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Semaglutide 0.5 mg
Intervention (Drug)
Semaglutide 1.0 mg
Intervention (Drug)
Sitagliptin placebo
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Semaglutide placebo 0.5 mg
Intervention (Drug)
Semaglutide placebo 1.0 mg
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct03061214
Content hash
1906b8345a71ab671bce60fd330daa2fe211349b3bdbc8880808389442c2cd0a